Correspondence
Artemisinin-Resistant Malaria in Asia
N Engl J Med 2009; 361:540-541July 30, 2009
- Article
To the Editor:
Artemisinin-based combination therapies have recently been introduced in virtually all countries in which malaria is endemic, thereby making such drugs the most essential class of antimalarial agents. The spread of artemisinin resistance could have a devastating effect on global malaria-control efforts. An important assumption in the use of such therapies is that the combination-drug partner will protect artemisinin from the development of resistance. However, recent data indicating that artemisinin resistance has already emerged along the border between Cambodia and Thailand suggest that this view may have been overly optimistic.1
On the basis of recent data, the World Health Organization is coordinating a large-scale malaria-elimination campaign in the region affected by artemisinin resistance.2 The central question emerging from the ongoing discussion is how far artemisinin resistance has extended westward from its original focus. Surveillance data from the Thai Ministry of Health indicate that clinical failures of artemisinin-based therapies are largely limited to the Thai–Cambodian border, whereas efficacy with artesunate–mefloquine along the western borders of Thailand remains high.3 In Cambodia, failure rates of artesunate–mefloquine are higher in the western provinces, which suggests that the current first-line therapy may be severely compromised in the region and that other options need to be evaluated. In vitro data can provide a quantitative measure of intrinsic artemisinin sensitivity, are well suited to show geographic trends, and may correlate with clinical response to treatment.
We conducted in vitro studies throughout South Asia and Southeast Asia, using a standardized approach (a histidine-rich protein 2 malaria in vitro drug-susceptibility assay4) at each site. On the basis of blood samples obtained from 247 patients between the ages of 18 and 65 years who presented with uncomplicated Plasmodium falciparum malaria (with 100 to 100,000 parasites per cubic millimeter), we found that artemisinin susceptibility showed a continuous and significant decrease from Bangladesh throughout western and eastern Thailand (Figure 1AFigure 1
In Vitro Sensitivity to Antimalarial Drugs in Bangladesh, Western Thailand, Eastern Thailand, and Cambodia.).In 49 samples collected in the Chittagong Hill Tracts in Bangladesh in 2004, the geometric mean 50% inhibitory concentration (IC50) was 1.33 nM (95% confidence interval [CI], 1.07 to 1.66). In 73 samples from patients originating in the Tak Province of western Thailand in 2004 and 2005, the IC50 was 1.87 nM (95% CI, 1.57 to 2.22).4 And in 37 samples collected in the Trat Province of eastern Thailand in 2005 and 2006, the IC50 was 3.18 nM (95% CI, 2.45 to 4.12). Levels in western Cambodia were similar to those in eastern Thailand. In 88 samples collected in Ta Sanh in the Battambang Province of Cambodia in 2006 and 2007, the IC50 was 3.34 nM (95% CI, 2.90 to 3.85).1,3,5 The corresponding mean value for the artemisinin-sensitive clone W2 was 1.51 nM.
It has been suggested that increased failure rates of artesunate–mefloquine in eastern Thailand, as compared with western Thailand, may be attributed to major regional differences in the susceptibility of malaria parasites to mefloquine, the partner drug used with artemisinin in Thailand. However, even though our data indicate a steep drop in mefloquine sensitivity between that measured in samples obtained in Bangladesh (IC50, 11.26 nM; 95% CI, 9.64 to 13.16) and that in samples obtained in western Thailand (IC50, 27.54 nM; 95% CI, 22.74 to 33.36; P<0.001), levels were similar in samples obtained in eastern Thailand (IC50, 24.49 nM; 95% CI, 18.62 to 32.22) and even lower in samples obtained in Cambodia (IC50, 16.55 nM; 95% CI, 12.32 to 22.23) (Figure 1B). Similarly high IC50 levels for mefloquine were found along both the eastern and western borders of Thailand (P=0.63), whereas the difference in artemisinin sensitivity between these sites was significant (P<0.001).
These findings suggest that the increased failure rate of artemisinin-based therapies can probably be attributed to decreased artemisinin susceptibility in the east rather than to major regional differences in mefloquine sensitivity. In southeastern Bangladesh, an area where until very recently artemisinin-based therapies have not been extensively used, artemisinin sensitivity remains high. These data indicate that it is unlikely that artemisinin resistance has spread across Thailand, and we found high susceptibility in Bangladesh.
5 ReferencesHarald Noedl, M.D., Ph.D.
Medical University of Vienna, A-1090 Vienna, Austria
harald.noedl@meduniwien. ac. at Duong Socheat, M.D.
National Center for Parasitology, Entomology, and Malaria Control, Phnom Penh, CambodiaWichai Satimai, M.D.
Ministry of Public Health, Nonthaburi 11000, Thailand1
Noedl H ,Se Y ,Schaecher K ,Smith BL ,Socheat D ,Fukuda MM . Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 2008;359:2619-2620
Full Text | Web of Science | Medline2
Enserink M . Malaria: signs of drug resistance rattle experts, trigger bold plan. Science 2008;322:1776-1776
CrossRef | Web of Science | Medline3
Vijaykadga S ,Rojanawatsirivej C ,Cholpol S , et al. In vivo sensitivity monitoring of mefloquine monotherapy and artesunate-mefloquine combinations for the treatment of uncomplicated falciparum malaria in Thailand in 2003. Trop Med Int Health 2006;11:211-219
CrossRef | Web of Science | Medline4
Noedl H ,Krudsood S ,Leowattana W , et al. In vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcome. Antimicrob Agents Chemother 2007;51:651-656
CrossRef | Web of Science | Medline5
Thriemer K ,Haque R ,Wagatsuma Y , et al. Therapeutic efficacy of quinine plus sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in Bangladesh. Am J Trop Med Hyg 2006;75:645-649
Web of Science | Medline
- Citing Articles (29)
Citing Articles
1
Deepa Ganesh, Hans-Peter Fuehrer, Peter Starzengrüber, Paul Swoboda, Wasif Ali Khan, Johannes A. B. Reismann, Milena S. K. Mueller, Peter Chiba, Harald Noedl. (2012) Antiplasmodial activity of flavonol quercetin and its analogues in Plasmodium falciparum: evidence from clinical isolates in Bangladesh and standardized parasite clones. Parasitology Research
CrossRef2
Probir Kumar Ojha, Kunal Roy. (2011) Comparative QSARs for antimalarial endochins: Importance of descriptor-thinning and noise reduction prior to feature selection. Chemometrics and Intelligent Laboratory Systems 109:2, 146-161
CrossRef3
S. Mharakurwa, T. Kumwenda, M. A. P. Mkulama, M. Musapa, S. Chishimba, C. J. Shiff, D. J. Sullivan, P. E. Thuma, K. Liu, P. Agre. (2011) Malaria antifolate resistance with contrasting Plasmodium falciparum dihydrofolate reductase (DHFR) polymorphisms in humans and Anopheles mosquitoes. Proceedings of the National Academy of Sciences 108:46, 18796-18801
CrossRef4
Papichaya Phompradit, Raewadee Wisedpanichkij, Poonuch Muhamad, Wanna Chaijaroenkul, Kesara Na-Bangchang. (2011) Molecular analysis of pfatp6 and pfmdr1 polymorphisms and their association with in vitro sensitivity in Plasmodium falciparum isolates from the Thai-Myanmar border. Acta Tropica 120:1-2, 130-135
CrossRef5
E.V.M. Kigondu, G.M. Rukunga, J.W. Gathirwa, B.N. Irungu, N.M. Mwikwabe, G.M. Amalemba, S.A. Omar, P.G. Kirira. (2011) Antiplasmodial and cytotoxicity activities of some selected plants used by the Maasai community, Kenya. South African Journal of Botany 77:3, 725-729
CrossRef6
Gundula Min-Oo, Philippe Gros. (2011) Genetic analysis in mice identifies cysteamine as a novel partner for artemisinin in the treatment of malaria. Mammalian Genome 22:7-8, 486-494
CrossRef7
F. Astelbauer, J. Walochnik. (2011) Antiprotozoal compounds: state of the art and new developments. International Journal of Antimicrobial Agents 38:2, 118-124
CrossRef8
Liwang Cui, Guiyun Yan, Jetsumon Sattabongkot, Bin Chen, Yaming Cao, Qi Fan, Daniel Parker, Jeeraphat Sirichaisinthop, Xin-zhuan Su, Henglin Yang, Zhaoqing Yang, Baomin Wang, Guofa Zhou. (2011) Challenges and prospects for malaria elimination in the Greater Mekong Subregion. Acta Tropica
CrossRef9
Sumit S. Mahajan, Edgar Deu, Erica M. W. Lauterwasser, Melissa J. Leyva, Jonathan A. Ellman, Matthew Bogyo, Adam R. Renslo. (2011) A Fragmenting Hybrid Approach for Targeted Delivery of Multiple Therapeutic Agents to the Malaria Parasite. ChemMedChem 6:3, 415-419
CrossRef10
Liwang Cui, Guiyun Yan, Jetsumon Sattabongkot, Yaming Cao, Bin Chen, Xiaoguang Chen, Qi Fan, Qiang Fang, Somchai Jongwutiwes, Daniel Parker, Jeeraphat Sirichaisinthop, Myat Phone Kyaw, Xin-zhuan Su, Henglin Yang, Zhaoqing Yang, Baomin Wang, Jianwei Xu, Bin Zheng, Daibin Zhong, Guofa Zhou. (2011) Malaria in the Greater Mekong Subregion: Heterogeneity and complexity. Acta Tropica
CrossRef11
Denis Matovu Kasozi, Stefan Rahlfs, Katja Becker. 2011. Current Aspects of Endoperoxides in Antiparasitic Chemotherapy. , 413-430.
CrossRef12
Henri J. Vial, Diana Penarete, Sharon Wein, Sergio Caldarelli, Laurent Fraisse, Suzanne Peyrottes. 2011. Lipids as Drug Targets for Malaria Therapy. , 137-162.
CrossRef13
Serena Tschan, Benjamin Mordmüller, Jürgen FJ Kun. (2011) Threonine peptidases as drug targets against malaria. Expert Opinion on Therapeutic Targets1-14
CrossRef14
Ksenija Slavic, Sanjeev Krishna, Elvira T Derbyshire, Henry M Staines. (2011) Plasmodial sugar transporters as anti-malarial drug targets and comparisons with other protozoa. Malaria Journal 10:1, 165
CrossRef15
Carsten Wrenger, Ingrid B. Müller, Anna J. Schifferdecker, Rishabh Jain, Rositsa Jordanova, Matthew R. Groves. (2011) Specific Inhibition of the Aspartate Aminotransferase of Plasmodium falciparum. Journal of Molecular Biology 405:4, 956-971
CrossRef16
Bruno Pradines, Lionel Bertaux, Christelle Pomares, Pascal Delaunay, Pierre Marty. (2011) Reduced in vitro susceptibility to artemisinin derivatives associated with multi-resistance in a traveller returning from South-East Asia. Malaria Journal 10:1, 268
CrossRef17
Carlos Moneriz, Patricia Marín-García, Andrés García-Granados, José M Bautista, Amalia Diez, Antonio Puyet. (2011) Parasitostatic effect of maslinic acid. I. Growth arrest of Plasmodium falciparum intraerythrocytic stages. Malaria Journal 10:1, 82
CrossRef18
Richard GA Feachem, Allison A Phillips, Jimee Hwang, Chris Cotter, Benjamin Wielgosz, Brian M Greenwood, Oliver Sabot, Mario Henry Rodriguez, Rabindra R Abeyasinghe, Tedros Adhanom Ghebreyesus, Robert W Snow. (2010) Shrinking the malaria map: progress and prospects. The Lancet 376:9752, 1566-1578
CrossRef19
Kathy Abascal, Eric Yarnell. (2010) Recent Clinical Advances with Berberine. Alternative and Complementary Therapies 16:5, 281-287
CrossRef20
Alexander Leeb, Gunther Wernsdorfer, Wichai Satimai, Ursula Wiedermann, Kanungnit Congpuong, Walther H. Wernsdorfer. (2010) Pharmacodynamic interaction between lumefantrine and desbutyl-benflumetol in Plasmodium falciparum in vitro. Wiener klinische Wochenschrift 122:S3, 61-65
CrossRef21
Martin Peter Grobusch, Michèle van Vugt. (2010) Malaria therapy: where do we stand, what next?. Future Microbiology 5:10, 1447-1449
CrossRef22
Edgar Deu, Melissa J. Leyva, Victoria E. Albrow, Mark J. Rice, Jonathan A. Ellman, Matthew Bogyo. (2010) Functional Studies of Plasmodium falciparum Dipeptidyl Aminopeptidase I Using Small Molecule Inhibitors and Active Site Probes. Chemistry & Biology 17:8, 808-819
CrossRef23
Rishabh Jain, Rositsa Jordanova, Ingrid B. Müller, Carsten Wrenger, Matthew R. Groves. (2010) Purification, crystallization and preliminary X-ray analysis of the aspartate aminotransferase of Plasmodium falciparum. Acta Crystallographica Section F Structural Biology and Crystallization Communications 66:4, 409-412
CrossRef24
Arjen M. Dondorp, Shunmay Yeung, Lisa White, Chea Nguon, Nicholas P.J. Day, Duong Socheat, Lorenz von Seidlein. (2010) Artemisinin resistance: current status and scenarios for containment. Nature Reviews Microbiology
CrossRef25
Johan van Griensven, Manica Balasegaram, Filip Meheus, Jorge Alvar, Lutgarde Lynen, Marleen Boelaert. (2010) Combination therapy for visceral leishmaniasis. The Lancet Infectious Diseases 10:3, 184-194
CrossRef26
Richard T. Eastman, David A. Fidock. (2009) Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nature Reviews Microbiology
CrossRef27
Harald Noedl. (2009) ABC - antibiotics-based combinations for the treatment of severe malaria?. Trends in Parasitology 25:12, 540-544
CrossRef28
Patricia Schlagenhauf, Eskild Petersen. (2009) Antimalaria drug resistance: the mono–combi–counterfeit triangle. Expert Review of Anti-infective Therapy 7:9, 1039-1042
CrossRef29
Campbell, Carlos C., . (2009) Malaria Control — Addressing Challenges to Ambitious Goals. New England Journal of Medicine 361:5, 522-523
Full Text
